Peipei Wang1, Cuizhen Zhang1, Qinyu Lv2, Chenxi Bao2, Hong Sun1, Guo Ma1, Yiru Fang2, Zhenghui Yi3, Weimin Cai4. 1. Department of Clinical Pharmacy, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai, 201203, People's Republic of China. 2. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wanping Rd, Shanghai, 200030, People's Republic of China. 3. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wanping Rd, Shanghai, 200030, People's Republic of China. yizhenghui1971@163.com. 4. Department of Clinical Pharmacy, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai, 201203, People's Republic of China. weimincai@fudan.edu.cn.
Abstract
PURPOSE: The neurotrophin brain-derived neurotrophic factor (BDNF) has been found to be associated with both the pathophysiology of depression and antidepressants response. Gene expression differences were partly mediated by SNP, which might be identified as a predictor of antidepressant response. In the present study, we attempt to identify whether DNA methylation, another factor known to affect gene transcription, might also predict antidepressant response. METHODS: A total of 85 depressed Chinese Han patients were followed-up 8 weeks after initiating escitalopram treatment. Treatment response was assessed by changes in the Hamilton Depression Rating Scale-17 (HAMD-17) score. The Life Events Scale (LES) and the Childhood Trauma Questionnaire (CTQ) were utilized as the assessment of previous life stress. The bisulfate sequencing was used to assess DNA methylation. Four single nucleotide polymorphisms (SNPs) in the BDNF gene were genotyped using PCR-RFLP or PCR sequencing. RESULTS: We identified a DNA methylation predictor (P = 0.006-0.036) and a DNA methylation by LES interaction predictor (OR = 1.442 [1.057-1.968], P = 0.021) of general antidepressant treatment response. Lower mean BDNF DNA methylation was associated with impaired antidepressant response. Furthermore, the present data indicated that age, life stress, and SNPs genotype might be likely related to DNA methylation status. Average DNA methylation of BDNF at baseline was significantly lower than that at endpoint after 8 weeks of escitalopram treatment, which was based only on a subset of cases (n = 44). CONCLUSIONS: Our results suggest that BDNF DNA hypomethylation and its interaction with lower LES score might result in impaired antidepressant treatment response. The pharmacoepigenetic study could eventually help in finding epigenetic biomarkers of antidepressant response.
PURPOSE: The neurotrophin brain-derived neurotrophic factor (BDNF) has been found to be associated with both the pathophysiology of depression and antidepressants response. Gene expression differences were partly mediated by SNP, which might be identified as a predictor of antidepressant response. In the present study, we attempt to identify whether DNA methylation, another factor known to affect gene transcription, might also predict antidepressant response. METHODS: A total of 85 depressed Chinese Han patients were followed-up 8 weeks after initiating escitalopram treatment. Treatment response was assessed by changes in the Hamilton Depression Rating Scale-17 (HAMD-17) score. The Life Events Scale (LES) and the Childhood Trauma Questionnaire (CTQ) were utilized as the assessment of previous life stress. The bisulfate sequencing was used to assess DNA methylation. Four single nucleotide polymorphisms (SNPs) in the BDNF gene were genotyped using PCR-RFLP or PCR sequencing. RESULTS: We identified a DNA methylation predictor (P = 0.006-0.036) and a DNA methylation by LES interaction predictor (OR = 1.442 [1.057-1.968], P = 0.021) of general antidepressant treatment response. Lower mean BDNF DNA methylation was associated with impaired antidepressant response. Furthermore, the present data indicated that age, life stress, and SNPs genotype might be likely related to DNA methylation status. Average DNA methylation of BDNF at baseline was significantly lower than that at endpoint after 8 weeks of escitalopram treatment, which was based only on a subset of cases (n = 44). CONCLUSIONS: Our results suggest that BDNF DNA hypomethylation and its interaction with lower LES score might result in impaired antidepressant treatment response. The pharmacoepigenetic study could eventually help in finding epigenetic biomarkers of antidepressant response.
Entities:
Keywords:
Brain-derived neurotrophic factor; DNA methylation; Escitalopram; Major depressive disorder; Polymorphism
Authors: Winfried Häuser; Eva-Maria Hoffmann; Frederick Wolfe; Angus B Worthing; Neil Stahl; Russell Rothenberg; Brian Walitt Journal: Clin Exp Rheumatol Date: 2015-03-18 Impact factor: 4.473
Authors: Rosie May Walker; Andrea Nikie Christoforou; Daniel L McCartney; Stewart W Morris; Nicholas A Kennedy; Peter Morten; Susan Maguire Anderson; Helen Scott Torrance; Alix Macdonald; Jessika Elizabeth Sussmann; Heather Clare Whalley; Douglas H R Blackwood; Andrew Mark McIntosh; David John Porteous; Kathryn Louise Evans Journal: Clin Epigenetics Date: 2016-01-20 Impact factor: 6.551
Authors: Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop Journal: J Affect Disord Date: 2019-02-06 Impact factor: 4.839
Authors: Stephanie H Parade; Lindsay Huffhines; Nicole R Nugent; Audrey R Tyrka; Teresa E Daniels; Laura R Stroud Journal: Transl Psychiatry Date: 2021-02-19 Impact factor: 6.222
Authors: Albert Martinez-Pinteño; Natalia Rodriguez; Ana Blázquez; Maria Teresa Plana; Eva Varela; Patricia Gassó; Amalia Lafuente; Luisa Lazaro; Sergi Mas Journal: Pharmgenomics Pers Med Date: 2021-04-19
Authors: Jiaqi Zhou; Miao Li; Xueying Wang; Yuwen He; Yan Xia; John A Sweeney; Richard F Kopp; Chunyu Liu; Chao Chen Journal: Front Neurosci Date: 2021-05-13 Impact factor: 4.677